Regeneron Pharmaceuticals REGN Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's retained earnings?
- Regeneron Pharmaceuticals (REGN) reported retained earnings of $36.42B in Q1 2026.
- How has Regeneron Pharmaceuticals's retained earnings changed year-over-year?
- Regeneron Pharmaceuticals's retained earnings increased by 12.5% year-over-year, from $32.38B to $36.42B.
- What is the long-term trend for Regeneron Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's retained earnings has grown at a 26.9% compound annual growth rate (CAGR), from $10.89B to $35.8B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.